III-01 Khaled Abduljalil Predicting the Developmental PK/PD of Cyclosporine (CsA) in Paediatrics Thursday 10:05-11:35 |
III-02 Mona Alameddine Pragmatic Approach for Interpreting Antiretroviral Drug Concentrations Based on a Systematic Review of Population Pharmacokinetic Studies Thursday 10:05-11:35 |
III-03 Azucena Aldaz Capecitabine: a pharmacokinetic model derived from its clinical use Thursday 10:05-11:35 |
III-04 Oskar Alskär Using allometric scaling on an integrated glucose insulin model for humans to investigate anti-diabetics drug effects in rats. Thursday 10:05-11:35 |
III-05 Claire Ambery Application of population dose-response and dose frequency in respiratory Thursday 10:05-11:35 |
III-06 Orna Amir Mechanistic NSCLC vascular tumor model: insights to prognosis towards personalized medicine Thursday 10:05-11:35 |
III-07 Jacqueline Anderson PKPD modelling of human chlorpyrifos poisoning Thursday 10:05-11:35 |
III-08 Eduardo Asín-Prieto Population pharmacokinetics of piperacillin in critically ill patients undergoing continuous renal replacement therapies Thursday 10:05-11:35 |
III-09 Bengt Hamren Log likelihood profile intervals for ED50 Thursday 10:05-11:35 |
III-10 Daren Austin A closed-form solution set-point model of treatment response in multiple diseases Thursday 10:05-11:35 |
III-11 Nicolas Azzopardi Modelization of bevacizumab effect on number of episodes of epistaxis in Hereditary Haemorrhagic Telangiectasia (HHT) Thursday 10:05-11:35 |
III-12 Gaurav Bajaj Model-based analysis of disease progression in pancreatic cancer based on registry data collected from the Surveillance, Epidemiology, and End Result (SEER) database Thursday 10:05-11:35 |
III-13 Francesco Bellanti Deferiprone sampling optimisation in a pharmacokinetic bridging study including children with β-thalassaemia Thursday 10:05-11:35 |
III-14 Brendan Bender A multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer Thursday 10:05-11:35 |
III-15 Margherita Bennetts Delta Method Application: Landmark Prediction and Confidence Interval for a Non-Linear Longitudinal Model Thursday 10:05-11:35 |
III-16 Aliénor Bergès Development of a mechanistic PK/PD model to guide dose selection of a combined treatment for systemic amyloidosis Thursday 10:05-11:35 |
III-17 Tarjinder Sahota A mechanistic PK/PD model to predict the pharmacological depletion of serum amyloid P component in healthy volunteers Thursday 10:05-11:35 |
III-18 Kirsten Bergmann Comparing a mechanistic with an empirical approach to assess resistance development of antibacterials in vitro. Thursday 10:05-11:35 |
III-19 Julie Bertrand Population Pharmacokinetic-Pharmacogenetic study of Efavirenz in combination with anti-TB treatment in HIV-Infected Cambodian Patients Thursday 10:05-11:35 |
III-20 Roberto Bizzotto Glucose Homeostasis Modeling: Improvement of the Insulin Action Component Thursday 10:05-11:35 |
III-21 Marcus Björnsson A population PK/PD model for bispectral index of the fast acting anesthetic AZD3043 in healthy volunteers Thursday 10:05-11:35 |
III-22 Michael Block Physiological modeling of inter-individual variability: Combining PBPK modeling and Markov-Chain-Monte-Carlo approaches Thursday 10:05-11:35 |
III-23 Michael Bolger GastroPlus PBPK/PD Model Applied to Estimating Dose for an Elderly Population in an Alzheimer’s Disease Clinical Trial Thursday 10:05-11:35 |
III-24 Irina Bondareva Population Pharmacokinetics of Phenytoin Estimated from Repeated Therapeutic Drug Monitoring (TDM) Data of Epileptic Patients Thursday 10:05-11:35 |
III-25 Emma Bostrom Modeling and Simulation of Pharmacokinetics and H3 Receptor Occupancy for Dose Setting in a Phase IIa Study Thursday 10:05-11:35 |
III-26 Salim Bouchene Whole Body Physiologically-Based Pharmacokinetic Model of Colistin and Colistimethate sodium in Critically Ill Patients Thursday 10:05-11:35 |
III-27 Marion Bouillon-Pichault Modeling of pain scores from a flexible titration study using an ordered categorical approaches Thursday 10:05-11:35 |
III-28 Frances Brightman Predicting in vivo drug response and synergistic combinations from three-dimensional tumour cell cultures Thursday 10:05-11:35 |
III-29 Margreke Brill Population pharmacokinetic model for cefazolin in serum and subcutaneous adipose tissue in morbidly obese and normal weight patients Thursday 10:05-11:35 |
III-30 Thierry Buclin Monitoring Blood Prostate-Specific Antigen (PSA) after Radical Prostatectomy Thursday 10:05-11:35 |
III-31 Núria Buil Bruna Modeling evaluation of different in vitro experimental designs to characterise antitumor drug effect Thursday 10:05-11:35 |
III-32 Theresa Cain A systems approach to predicting differences in pharmacological response to a CYP1A2 substrate, resulting from pharmacokinetic differences in non-smokers, passive smokers and heavy smokers Thursday 10:05-11:35 |
III-33 Sophie Callies Sensitivity analysis to help the assessment of variance: application to Target Mediated Drug Disposition (TMDD) PK/PD model describing the effect of a monoclonal antibody (mAb) on a circadian biomarker. Thursday 10:05-11:35 |
III-34 Yu-Jung Cha Population Pharmacokinetics of Etanercept in Healthy Korean Male Volunteers Thursday 10:05-11:35 |
III-35 Quentin Chalret du Rieu Semi-mechanistic thrombocytopenia model of a new histone deacetylase inhibitor (HDACi) in development, with a drug-induced apoptosis of megakaryocytes. Thursday 10:05-11:35 |
III-36 Pascal Chanu On the use of hemodynamics biomarkers to assess the benefit of high doses of sildenafil in some patients with pulmonary arterial hypertension (PAH) Thursday 10:05-11:35 |
III-37 Ayyappa Chaturvedula Development of population pharmacokinetic model for Tenofovir using sparsely sampled subject data Thursday 10:05-11:35 |
III-38 Chao Chen Quantifying the Effectiveness of Dose Personalisation by Simulation for a Drug with Moderate Pharmacokinetic Variability Thursday 10:05-11:35 |
III-39 Marylore Chenel In vitro – in vivo correlation by population approach applied to modified-release forms with double-peak absorption Thursday 10:05-11:35 |
III-40 S. Y. Amy Cheung An update on structural identifiability of parallel pharmacokinetic experiments viewed as constrained systems Thursday 10:05-11:35 |
III-42 Karina Blei Development and evaluation of dynamical whole body Physiologically-based Models of the Circulation and the Renin-Angiotensin-Aldosterone system Thursday 10:05-11:35 |
III-43 Laurent Claret Evaluation of Tumor-Size Response Metrics to Predict Survival and Progression Free Survival in First-Line Metastatic Colorectal Cancer Thursday 10:05-11:35 |
III-44 Francois Combes Prediction of precision of individual parameter estimates and of shrinkage via the Bayesian Fisher information matrix in non-linear mixed-effects models with application in pharmacokinetics Thursday 10:05-11:35 |
III-45 Emmanuelle Comets Dealing with BQL data in normalised prediction distribution errors: a new version of the npde library for R Thursday 10:05-11:35 |
III-46 Damien Cronier Population Pharmacokinetic Study of a New Humanized Anti-CD20 Monoclonal Antibody AME-133v (LY2469298) in Patients with Previously Treated Folicular Lymphoma. Thursday 10:05-11:35 |
III-47 Zeinab Daher Abdi Joint model for longitudinal exposure to mycophenolic acid and rejection survival data in the first year after renal transplantation Thursday 10:05-11:35 |
III-48 Elyes Dahmane The influence of CYP2D6 genetic polymorphism on tamoxifen and its active metabolite exposure in breast cancer patients: preliminary results from a prospective, open-label trial. Thursday 10:05-11:35 |
III-49 Adam Darwich Development and application of a mechanistic physiologically based pharmacokinetic model to assess oral drug bioavailability post bariatric surgery in morbidly obese patients Thursday 10:05-11:35 |
III-50 Ruben de Kanter The impact of using the well-stirred liver model in PBPK modelling for high-clearance compounds Thursday 10:05-11:35 |
III-51 Giuseppe De Nicolao PCA-based modelling in antidepressant trials: a pre-mechanistic approach Thursday 10:05-11:35 |
III-52 Ivan Demin Posterior predictive check to assess similarity of systemic exposure profiles of an inhaled drug product pre- and post- manufacturing modification. Thursday 10:05-11:35 |
III-53 Paolo Denti Population pharmacokinetics of ritonavir-boosted darunavir together with efavirenz in healthy volunteers Thursday 10:05-11:35 |
III-54 Kristin Dickschen Evaluation of CYP2D6 Phenotype-Guided Tamoxifen Dosing in European Female Breast Cancer Patients using a PBPK-Model Thursday 10:05-11:35 |
III-55 Christian Diestelhorst A Physiologically-Based Pharmacokinetic Model for Busulfan Thursday 10:05-11:35 |
III-56 Nassim Djebli Pharmacokinetic/pharmacodynamic (PK/PD) Analysis of Teriflunomide in Patients with Relapsing Forms of Multiple Sclerosis (RMS) Thursday 10:05-11:35 |
III-57 Jennifer Dong Assessment of Mechanism of Action and Drug Effects in Early Signal of Efficacy Trials Using Integrated Glucose-Insulin Modeling: A Simulation-Estimation Approach Thursday 10:05-11:35 |
III-58 Pinky Dua A Systems Pharmacology model of the nerve growth factor (NGF) pathway to aid drug discovery and development Thursday 10:05-11:35 |
III-59 Vivek Dua Multi-objective Optimal Control of Non-Viral Gene Delivery Thursday 10:05-11:35 |
III-60 Anne Dubois Joint modelling of the placebo response and the dropout mechanism using clinical data from a trial performed in patients suffering from major depressive disorder Thursday 10:05-11:35 |
III-61 Cyrielle Dumont Optimal two-stage design for a population pharmacokinetic study in children Thursday 10:05-11:35 |
III-62 Jeroen Elassaiss-Schaap Pharmacokinetic-Pharmacodynamic Modelling & Simulation of Org 52186, a V3 antagonist, in Support of a Challenge Agent Trial Design with dDAVP Thursday 10:05-11:35 |
III-63 Farkad Ezzet Power Calculation Based on Pharmacokinetic Sampling Designs of ELND005 in a Phase 3 Clinical Trial Design in Mild Alzheimer Disease Patients Thursday 10:05-11:35 |
III-64 Iñaki F. Trocóniz Exploratory analysis to evaluate the relevance of different mechanism involved in a bivariate response target mediated disposition model characterizing the IL12 – IFNγ relationship. Thursday 10:05-11:35 |
III-65 Christine Falcoz Population PKPD modeling of an anti-diabetic compound with a new mechanism of action in ob/ob mice to predict the human dose Thursday 10:05-11:35 |
III-66 Mathieu Felices Dose Regimen Assessement For Oral Fexinidazole Thursday 10:05-11:35 |
III-67 Gregory Ferl A mixed-effects simulation approach to quantifying the impact of missing pre-treatment baseline clinical DCE-MRI data on estimated population parameters Thursday 10:05-11:35 |
III-68 Eric Fernandez A database of PK-PD parameters and information for the modelling of anti-cancer drug regimen and combinations Thursday 10:05-11:35 |
III-69 Martin Fink Population pharmacokinetic analysis of robenacoxib in dogs with chronic osteoarthritis Thursday 10:05-11:35 |